Vidutolimod
As of the edition of 20 October 2026, Vidutolimod is a drug: in active development; acts on TLR9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Unknown
- Registered trials
- 15, 6 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Lungs and airways; Digestive system; Blood and lymph; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TLR9 | Toll-like receptor 9 | Q9NR96 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 9 | 2 | 2 | 5 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 15 |